refractory small lymphocytic lymphoma
Showing 1 - 25 of >10,000
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Duarte, California
- +2 more
Oct 7, 2022
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +4 more
- Daratumumab
- Ibrutinib
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Completed
- Loss of Chromosome 17p
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Zhengzhou, Nanjing (TQB3909 tablet)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- TQB3909 tablet
-
Zhengzhou, Henan, China
- +1 more
Jul 17, 2023
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)
Withdrawn
- Chronic Lymphocytic Leukemia
- +8 more
- Dose combination 1-1
- +5 more
- (no location specified)
Nov 1, 2021
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jul 14, 2022
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
-
Bethesda, MarylandResearch Site
Jan 3, 2023
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma Trial in Italy, United
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
- brexucabtagene autoleucel
- +2 more
-
Phoenix, Arizona
- +21 more
Jun 2, 2022
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,
Terminated
- Diffuse Large B Cell Lymphoma
- +3 more
- Acalabrutinib
- +4 more
-
Miami, FloridaUniversity of Miami
Aug 23, 2022
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Active, not recruiting
- Relapsed/Refractory B Cell Malignancies
- +3 more
-
Columbus, Ohio
- +17 more
Aug 18, 2022
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022